Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

human heterologous liver cells

HEPARESC

human heterologous liver cells (HEPARESC) is an FDA-listed pharmaceutical active ingredient.

EMA: refused Alimentary tract and metabolism (A16) A16
Patents linked 17
Pipeline programs 69
News articles 0
Drug details — human heterologous liver cells
Class
Alimentary tract and metabolism (A16)
Route
—
Patents
17
Programs
69
Data quality
0.83
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

human heterologous liver cells (HEPARESC) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN human heterologous liver cells
Brand HEPARESC
Therapeutic class Alimentary tract and metabolism (A16)
ATC code A16

Approval history

Authority Status Date
EMA refused —

Pipeline programs

Browse pipeline
  1. 040201 Phase 3 · Takeda · Hemophilia A
  2. 160701 Phase 3 · Takeda · Alzheimer´s Disease
  3. 161003 Phase 3 · Takeda · Alzheimer´s Disease
  4. 161202 Phase 3 · Takeda · Alzheimer´s Disease
  5. 170904 Phase 3 · Takeda · Primary Immunodeficiency Diseases (PID)
  6. 221672 Phase 3 · GSK Glaxo Smith · Lung Diseases, Interstitial
  7. ARGX-117-2401 Phase 3 · Argenx · Chronic inflammatory demyelinating polyneuropathy (CIDP)
  8. CYD32 Phase 3 · Sanofi Pasteur MSD · Dengue Fever

Related & competitor drugs

Browse all drugs
  1. agalsidase alfa Alimentary tract and metabolism (A16)
  2. alogliptin Alimentary tract and metabolism (A10)
  3. alogliptin benzoate Alimentary tract and metabolism (A10)
  4. aprepitant Alimentary tract and metabolism (A04)
  5. budesonide Alimentary tract and metabolism (A07)
  6. canagliflozin Alimentary tract and metabolism (A10)

Related patents

Browse patents

  1. WO 2022258590

    PROCÉDÉ D'ISOLEMENT DE PLASMINOGÈNE À PARTIR D'UNE FRACTION DE PLASMA SANGUIN

    Expires Wed Dec 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. DK 2928905

    FREMGANGSMÅDE TIL OPRENSNING AF TERAPEUTISKE PROTEINER

    Expires Sun Mar 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. CA 3072003

    PROCEDE DE FILTRATION VIRALE DU FACTEUR DE VON WILLEBRAND

    Expires Wed Feb 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 2018264111

    PHARMACEUTICAL PRODUCT WITH INCREASED STABILITY COMPRISING IMMUNOGLOBULINS

    Expires Wed Sep 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. CA 3034568

    PROCEDE DE PREVENTION D'ATTAQUES AIGUES D'OEDEME DE QUINCKE HEREDITAIRE ASSOCIEES A UNE DEFICIENCE EN INHIBITEUR DE C1 ESTERASE

    Expires Wed Feb 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. EP 3193911

    VERBESSERTE FAKTOR-VIII-PRÄPARATIONEN FÜR THERAPEUTISCHE VERWENDUNG UND VERFAHREN ZUR ERHALTUNG DERSELBEN

    Expires Tue Jul 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. EP 3013366

    KOMBINATIONSTHERAPIE MIT EINEM FAKTOR XII-HEMMER UND EINEM C1-HEMMER

    Expires Tue Apr 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. EP 2964255

    BEHANDLUNG UND VORBEUGUNG VON REMOTER ISCHÄMISCHER REPERFUSION

    Expires Tue Jan 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. EP 2961422

    THERAPEUTIKUM FÜR FRUCHTWASSEREMBOLIE

    Expires Tue Jan 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 2015366947

    A Method of Purifying Therapeutic Proteins

    Expires Wed Dec 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. CA 2943376

    NEBULISATION D'IMMUNOGLOBULINE

    Expires Wed Oct 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 2015158906

    Method of Purifying Therapeutic Proteins

    Expires Wed Jun 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. EP 2846808

    ZUCKERZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON HÄMOPHILIE A UND/ODER VON-WILLEBRAND-SYNDROM

    Expires Tue Mar 13 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 2014357564

    Von Willebrand Factor Variants Having Improved Factor VIII Binding Affinity

    Expires Wed Nov 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. EP 2796145

    EIN KOVALENTER KOMPLEX BESTEHEND AUS VON WILLEBRAND UND FAKTOR VIII VERBUNDEN MIT EINER DISULFIDBRÜCKE

    Expires Tue Oct 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. EP 2623110

    Faktor-XII-Hemmer zur Behandlung neurologischer Entzündungserkrankungen

    Expires Tue Aug 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. CA 2852397

    UTILISATION DE GLYCOSAMINOGLYCANES SULFATES POUR AMELIORER LA BIODISPONIBILITE DU FACTEUR VIII

    Expires Wed Apr 20 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is human heterologous liver cells?

human heterologous liver cells (HEPARESC) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for human heterologous liver cells?

HEPARESC is a marketed brand name for human heterologous liver cells. Check FDA Drugs@FDA for the current US label holder and prescribing information.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.